Roche

13 atoms · 跨 8 天 · 首见 2026-04-17 · 最近 2026-07-02

三色: 🟦 fact 11 · 🟥 take 2 · stance ▲5/▼1/◆5

来源: X 13

时态: fresh:11 · aging:2

标签: 好信源:8 · 好数字:5 · 好观点:2

叙事 (narrative) (2)

• 2026-04-23 [老化中] · 高管表述
  Roche chief executive : China is trending positively
  tags: 好信源 · → daily
  value: date=2026-04-23 · direction=正
• 2026-04-17 [老化中] · 新研究
  Analyst sees rising efficacy risks from new Roche study
  tags: 好观点 · → daily

预测 (forecast) (1)

• 2026-04-23 · 部门业绩预期
  diagnostics set to perform better in H2 than H1
  tags: 好观点 · → daily
  value: qty=better · date=H2比H1 · direction=正

事实 (fact) (10)

• 2026-07-02 ⭐ · lung-cancer drug candidate beats existing therapies in late-stage trial
  ROCHE LUNG-CANCER DRUG CANDIDATE BEATS EXISTING THERAPIES IN LATE-STAGE TRIAL- WSJ
  tags: 好数字·好信源 · → daily
• 2026-05-07 ⭐ · acquisition of PathAI
  Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026
  tags: 好数字·好信源 · → daily
  value: qty=$1.05B · date=H2 2026
• 2026-06-18 · FDA 接受 sBLA
  Roche announced that the FDA has accepted its sBLA for Lunsumio combined with Polivy in large B-cell lymphoma
  tags: 好信源 · → daily
  value: qty=Lunsumio combined with Polivy in large B-cell lymphoma
• 2026-06-18 · 监管行动预期日期
  with regulatory action expected by 9 February 2027
  tags: 好数字 · → daily
  value: date=2027-02-09
• 2026-06-11 · FDA priority review status for Tecentriq in stage III colon cancer
  Roche reports FDA priority review for Tecentriq in specific stage III colon cancer indication
  tags: 好信源 · → daily
  value: date=2026-06-11
• 2026-06-08 · 签署收购协议
  ROCHE ENTERS $2.3 BILLION BLOOD-CANCER DRUG DEAL WITH NURIX THERAPEUTICS – WSJ
  tags: 好信源 · → daily
  value: qty=$2.3B · direction=buy
• 2026-06-02 · FDA accepts new drug application for giredestrant in ER-positive early-stage breast cancer
  FDA accepts Roche’s new drug application for giredestrant in ER-positive early-stage breast cancer, following positive Phase III results.
  tags: 好信源 · → daily
• 2026-06-02 · giredestrant 3年生存与无病率
  Roche reports 92.4% 3-year survival and disease-free rate for giredestrant patients versus 89.6% with standard treatment.
  tags: 好数字 · → daily
  value: qty=92.4% · date=3年
• 2026-07-02 · new lung cancer pill trial result
  ROCHE'S NEW LUNG CANCER PILL BEAT TWO APPROVED DRUGS IN A LATE-STAGE TRIAL, IMPROVING THE SWISS COMPANY'S CHANCES OF LAUNCHING A NEXT-GEN TREATMENT.
  tags: 好信源 · → daily
• 2026-06-08 · 协议向Nurix支付最高金额
  Roche agreed to pay Nurix $NRIX up to $2.3B for rights to bexobrutideg, its experimental blood-cancer drug.
  tags: 好数字 · → daily
  value: qty=$2.3B · date=2026-06-08

时间轴 (近 20)

• 2026-07-02 · fact · lung-cancer drug candidate beats existing therapies in late- · → daily
• 2026-07-02 · fact · new lung cancer pill trial result · → daily
• 2026-06-18 · fact · FDA 接受 sBLA · → daily
• 2026-06-18 · fact · 监管行动预期日期 · → daily
• 2026-06-11 · fact · FDA priority review status for Tecentriq in stage III colon · → daily
• 2026-06-08 · fact · 签署收购协议 · → daily
• 2026-06-08 · fact · 协议向Nurix支付最高金额 · → daily
• 2026-06-02 · fact · FDA accepts new drug application for giredestrant in ER-posi · → daily
• 2026-06-02 · fact · giredestrant 3年生存与无病率 · → daily
• 2026-05-07 · fact · acquisition of PathAI · → daily
• 2026-04-23 · narrative · 高管表述 · → daily
• 2026-04-23 · forecast · 部门业绩预期 · → daily
• 2026-04-17 · narrative · 新研究 · → daily

← 实体目录 · 系统日志